-
公开(公告)号：US20240165232A1
公开(公告)日：2024-05-23
申请号：US17279561
申请日：2019-09-23
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/715 , C07K14/725 , C07K16/28 , C12N5/0783
CPC分类号： A61K39/464412 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/7151 , C07K16/2803 , C12N5/0636 , C07K2317/622 , C07K2319/03 , C07K2319/30 , C12N2510/00
摘要： The present disclosure provides fusion proteins with improved signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular antigen-binding domain, a transmembrane domain, and an intracellular component comprising one or more domain or motif from a CD3ε, γ, or δ protein, and have improved signaling in response to antigen-binding, including of antigens with reduced, low, or intermediate levels of expression on a target cell, such as a solid tumor cell. Recombinant host cells expressing the fusion proteins are also provided, as well as compositions and methods comprising the same.
-
公开(公告)号：US20220267437A1
公开(公告)日：2022-08-25
申请号：US17631399
申请日：2020-07-28
IPC分类号： C07K16/28 , C07K14/705
摘要： The disclosure provides methods for inducing Notch signaling in a targeted manner within aggregations of cells. The methods include contacting the aggregation of cells with a bi-specific molecule that facilitates trans-binding of Notch receptor. The bi-specific molecule comprising a cell-targeting domain that specifically binds to a cell-specific antigen expressed in the aggregation of cells, and a Notch-binding domain that specifically binds to Notch receptor. In some aspects, the disclosed methods and reagents provide methods of promoting pro-inflammatory states in tumor micro-environments.
-
公开(公告)号：US20220249439A1
公开(公告)日：2022-08-11
申请号：US17629333
申请日：2020-07-23
发明人： Andrew Hsieh
IPC分类号： A61K31/4025 , A61K31/427 , A61K31/426 , A61K31/4166 , A61K31/277 , A61K31/4439 , A61K31/167 , A61K31/58 , A61K31/4188 , A61K38/09 , A61K31/519 , A61P35/00
摘要： Methods and compositions for treatment of prostate cancers, such as androgen receptor (AR) deficient and androgen receptor (AR) low cancers, are disclosed. The methods include administration of an agent that inhibits activity of eIF4F or an agent that disrupts the eIF4F translation-initiation complex (composed of eIF4E, eIF4A, and eIF4G).
-
公开(公告)号：US20220204935A1
公开(公告)日：2022-06-30
申请号：US17524592
申请日：2021-11-11
IPC分类号： C12N5/0789 , C12N15/86 , A61K39/00 , A61K35/28 , C07K14/725 , C07K14/705 , C07K14/715 , C07K16/28 , C12N5/0783 , G01N33/569
摘要： Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to activate, promote proliferation of, detect, enrich, isolate, track, deplete and/or eliminate modified cells. The cells can also be modified to express a binding domain.
-
公开(公告)号：US20220160832A1
公开(公告)日：2022-05-26
申请号：US17643410
申请日：2021-12-08
发明人： Rachel PERRET , Philip D. GREENBERG , Thomas M. SCHMITT , Aude G. CHAPUIS , Ingunn M. STROMNES , Tijana MARTINOV
摘要： The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.
-
公开(公告)号：US20220160764A1
公开(公告)日：2022-05-26
申请号：US17438380
申请日：2020-03-10
IPC分类号： A61K35/17 , C07K14/725 , C12N5/0783 , A61P35/00
摘要： The present disclosure provides T cell receptors (TCRs) and related binding proteins with high functional avidity against tumor associated antigen p37 from Wilms tumor protein 1 (WT1), T cells expressing such high affinity WT1 specific TCRs, nucleic acids encoding the same, and compositions for use in treating diseases or disorders in which cells overexpress WT1 and/or produce the p37 antigen, such as in cancer.
-
公开(公告)号：US20220106623A1
公开(公告)日：2022-04-07
申请号：US17296038
申请日：2019-11-21
发明人： Jason Bielas
IPC分类号： C12Q1/6804 , G01N33/574 , C12Q1/686 , C12Q1/6874 , C12N15/10
摘要： Systems and methods to tag cells in a tissue sample with spatial identifiers, so that spatial reconstruction of cell locations within a tissue can be achieved after tissue disaggregation are described. The systems and methods allow the control or directing of specific spatial identifiers spatially within or throughout a tissue to individual cells or to a small population of cells so that cell position can be determined by computational deconvolution of the spatial identifiers after tissue disaggregation. The systems and methods can be combined with single cell expression analysis to correlate cell types with cell location within a structure, such as a tumor.
-
公开(公告)号：US20220098613A1
公开(公告)日：2022-03-31
申请号：US17276105
申请日：2019-09-12
IPC分类号： C12N15/86 , C07K16/28 , A61K35/28 , A61K47/68 , A61P37/04 , A61K39/395 , C12N15/113 , A61K31/7088
摘要： Systems and methods to selectively protect therapeutic cells by reducing CD33 expression in the therapeutic cells and targeting non-therapeutic cells with an anti-CD33 therapy. The selective protection results in the enrichment of the therapeutic cells while simultaneously targeting any diseased, malignant and/or non-therapeutic CD33 expressing cells within a subject.
-
公开(公告)号：US20220073879A1
公开(公告)日：2022-03-10
申请号：US17400038
申请日：2021-08-11
发明人： Cassian YEE , Yongqing LI
IPC分类号： C12N5/0783 , A61K31/41 , A61K39/00 , A61P35/00 , A61K35/17
摘要： A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
-
10.发明授权公开(公告)号：US11261250B2
公开(公告)日：2022-03-01
申请号：US16318313
申请日：2017-07-20
申请人： Fred Hutchinson Cancer Research Center , The Board of Trustees of The Leland Stanford Junior University
IPC分类号： C07K14/705 , C07K14/475 , C07K16/28 , C07K19/00 , C12N15/63 , C12N5/10 , C07K16/22 , A61P35/00 , C07K16/46 , G01N33/566 , G01N33/574
摘要： This disclosure provides compositions and related methods providing targeted cell-specific inhibition of Notch receptor signaling. The disclosure provides a bi-specific molecule with separate domains that target the intended cell-type and the Notch receptor on that cell-type. The disclosure also provides for nucleic acids, vectors, and cells allowing for the expression of the bi-specific fusion molecules. The disclosure also provides related methods of making and using the bi-specific fusion molecule to inhibit Notch signaling in target cells of interest, including for the treatment of diseases characterized by a dysregulation of Notch signaling.
-
-
-
-
-
-
-
-
-
搜索结果
474 条记录 (耗时 0.035 秒)
